DelveInsight reports that the Natural Killer (NK) Cell Therapies pipeline involves over 100 key companies actively developing more than 140 therapeutic candidates.
Natural Killer Cell Therapies Overview:
Natural killer (NK) cells are a type of lymphocyte that play a vital role in the innate immune system. These specialized immune cells are key defenders against tumors and virus-infected cells. In cancer patients, NK cells often exhibit abnormalities, including reduced cytotoxic activity, impaired expression of activating receptors or signaling proteins, increased levels of inhibitory receptors, limited proliferation, decreased presence in the bloodstream and tumor tissues, and disrupted cytokine production.
NK cell-based therapies have demonstrated particular promise in treating blood cancers like leukemia. Approaches to NK immunotherapy generally involve either activating the patient’s own NK cells using specific stimulators or introducing externally sourced NK cells via methods such as hematopoietic stem cell transplantation (HSCT) or adoptive cell transfer. Numerous strategies have now been developed to leverage NK cells in cancer treatment.
Download our report @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Natural Killer Cell Therapies Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Natural Killer Cell Therapies Therapeutics Market.
Key Takeaways from the Natural Killer Cell Therapies Pipeline Report
DelveInsight’s report on the Natural Killer (NK) Cell Therapies pipeline highlights a dynamic landscape, with over 100 companies actively developing more than 140 therapeutic candidates.
Key regulatory updates include:
-
June 2024: GT Biopharma received FDA clearance for its IND application for GTB-3650, an NK cell engager targeting CD33+ leukemia, with Phase 1 trials anticipated in the second half of 2024.
-
April 2024: The FDA approved ANKTIVA (an IL-15 receptor agonist) for BCG-unresponsive non-muscle invasive bladder cancer, which works by activating the body’s NK and T cells to target tumor cells.
-
April 2024: NKGen Biotech obtained FDA IND clearance to begin a Phase 1/2a trial of SNK01, an autologous NK cell therapy for Parkinson’s disease.
Leading companies advancing NK cell therapies include ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (formerly Cell Medica), and others.
Promising NK cell therapy candidates in development include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT-803, ALECSAT, PNK-007, among several others.
Natural Killer Cell Therapies Pipeline Analysis
The Natural Killer Cell Therapies pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Natural Killer Cell Therapies Market.
-
Categorizes Natural Killer Cell Therapies therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Natural Killer Cell Therapies drugs under development based on:
-
Stage of development
-
Natural Killer Cell Therapies Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Natural Killer Cell Therapies Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Natural Killer Cell Therapies Licensing agreements
-
Funding and investment activities supporting future Natural Killer Cell Therapies market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Natural Killer Cell Therapies Emerging Drugs
-
Monalizumab: Innate Pharma
-
NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
-
ALT 803: ImmunityBio
-
ALECSAT: CytoVac
-
PNK-007: Celularity
Natural Killer Cell Therapies Companies
More than 100 leading companies are actively developing Natural Killer (NK) Cell Therapies, with Innate Pharma advancing a drug candidate to the most advanced stage—Phase III clinical trials.
DelveInsight’s report covers around 140+ products under different phases of Natural Killer Cell Therapies clinical trials like
-
Natural Killer Cell Therapies Late stage Therapies (Phase III)
-
Natural Killer Cell Therapies Mid-stage Therapies (Phase II)
-
Natural Killer Cell Therapies Early-stage Therapies (Phase I)
-
Natural Killer Cell Therapies Pre-clinical and Natural Killer Cell Therapies Discovery stage Therapies
-
Natural Killer Cell Therapies Discontinued & Inactive Therapies
Natural Killer Cell Therapies pipeline report provides the Natural Killer Cell Therapies therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Natural Killer Cell Therapies Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Natural Killer Cell Therapies Therapies and Key Natural Killer Cell Therapies Companies: Natural Killer Cell Therapies Clinical Trials and recent advancements
Natural Killer Cell Therapies Pipeline Therapeutic Assessment
• Natural Killer Cell Therapies Assessment by Product Type
• Natural Killer Cell Therapies By Stage
• Natural Killer Cell Therapies Assessment by Route of Administration
• Natural Killer Cell Therapies Assessment by Molecule Type
Download Natural Killer Cell Therapies Sample report to know in detail about the Natural Killer Cell Therapies treatment market @ Natural Killer Cell Therapies Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Natural Killer Cell Therapies Current Treatment Patterns
4. Natural Killer Cell Therapies - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Natural Killer Cell Therapies Late-Stage Products (Phase-III)
7. Natural Killer Cell Therapies Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Natural Killer Cell Therapies Discontinued Products
13. Natural Killer Cell Therapies Product Profiles
14. Natural Killer Cell Therapies Key Companies
15. Natural Killer Cell Therapies Key Products
16. Dormant and Discontinued Products
17. Natural Killer Cell Therapies Unmet Needs
18. Natural Killer Cell Therapies Future Perspectives
19. Natural Killer Cell Therapies Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Natural Killer Cell Therapies Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
